Real-Life Management of Patients with Retinal Vein Occlusion Using I-Macula Web Platform

Table 5

Exposure to drug in 37 eyes with macular edema secondary to retinal vein occlusion treated with DEX implant and/or ranibizumab.

	RVO	CRVO	BRVO
Total (s; m)	37 (111; 2.36)	17 (51; 2.55)	20 (60; 2.2)
DEX (s; m)	27 (62; 2.29)	14 (35; 2.5)	13 (27; 2.07)
DEX + RBZ (s; m)	10 (49; 4.9)	3 (12; 4)	7 (22; 3.14)
DEX
RBZ

s: number of injections; m: mean number of injection.